Use of Activated Recombinant FVII in Spinal Surgery
Public ClinicalTrials.gov record NCT00102037. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Study identification
- NCT ID
- NCT00102037
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Interventions
- eptacog alfa (activated) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2004
- Primary completion
- Jan 31, 2006
- Completion
- Jan 31, 2006
- Last update posted
- Jan 12, 2017
2004 – 2006
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Sacramento | California | 95817 | — |
| Novo Nordisk Investigational Site | San Francisco | California | 94143-0728 | — |
| Novo Nordisk Investigational Site | Washington D.C. | District of Columbia | 20007 | — |
| Novo Nordisk Investigational Site | Miami | Florida | 33136 | — |
| Novo Nordisk Investigational Site | Atlanta | Georgia | 30322 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60612 | — |
| Novo Nordisk Investigational Site | Newark | New Jersey | 07103 | — |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| Novo Nordisk Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75246 | — |
| Novo Nordisk Investigational Site | Plano | Texas | 75093 | — |
| Novo Nordisk Investigational Site | Charlottesville | Virginia | 22908 | — |
| Novo Nordisk Investigational Site | Richmond | Virginia | 23298-0541 | — |
| Novo Nordisk Investigational Site | Seattle | Washington | 98104-2499 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00102037, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 12, 2017 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00102037 live on ClinicalTrials.gov.